<DOC>
	<DOCNO>NCT00721045</DOCNO>
	<brief_summary>This dose-ranging clinical study evaluate feasibility , safety , tolerability 3 different dos immunoselected , culture expand , nucleate , allogeneic MPCs subject cardiomyopathy ischemic idiopathic etiology .</brief_summary>
	<brief_title>A Phase II Dose-escalation Study Assess Feasibility Safety Transendocardial Delivery Three Different Doses Allogeneic Mesenchymal Precursor Cells ( MPCs ) Subjects With Heart Failure</brief_title>
	<detailed_description>Heart failure subject recruit include advanced heart failure NYHA ( New York Heart Association ) class II IV depress ejection fraction ( EF &lt; 40 % ) . Baseline eligibility test assessment complete within 28 day prior cell delivery . Efficacy explore 3 , 6 , 12 month . This single-blinded , dose-escalation , cohort study 60 subject allocate sequentially 1 3 cohort A , B , C. Forty-five subject randomize receive transendocardial delivery MPC treatment , 15 subject randomize receive standard-of-care treatment without MPC administration . The fifteen subject randomize receive standard care without needle injection serve study 's control population undergo mock mapping verbal injection script .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . NYHA ≥ 2 . 2 . Age &gt; 20 &lt; 80 . 3 . Cardiomyopathy ischemic idiopathic etiology . 4 . Subject candidate either percutaneous intervention cardiac surgery determine interventional cardiologist cardiac surgeon . 5 . LVEF ( Left ventricular ejection fraction ) &lt; 40 % via 2D Echocardiogram within 28 day study procedure . 6 . On stable maximal , tolerable dosage heart failure therapy include betablockers , ace inhibitor and/or diuretic interruption change medical therapy least 28 day prior study enrollment . 7 . Left Ventricle wall thickness ≥ 8mm target site echo within 28 day study procedure . 8 . If subject partner childbearing potential , must willing use adequate contraception ( hormonal barrier method abstinence ) time screen period least 16 week procedure . 9 . Female subject childbearing potential must negative serum pregnancy test screening . 10 . Willing able understand , sign , date Informed Consent Form ( ICF ) . 11 . Must willing return require followup visit . 12 . Must able follow postoperative management program . 1 . Acute Myocardial Infarction past 30 day . 2 . Discharge subject 's ICD within 28 day study procedure . 3 . Sustained Ventricular Tachycardia demonstrate QRS complex wider 120 msec , last &gt; 30 sec , &gt; 100 bpm document screen ECG 24 hour Holter monitoring . 4 . Unstable angina . 5 . LV thrombus echocardiogram angiogram 28 day prior time cell injection . 6 . Aortic stenosis determine echocardiography valve area le 1 cm2 prohibits NOGA catheter access LV . 7 . Cardiogenic shock define need intravenous inotropic support , intraaortic balloon pump , mechanical circulatory support time cell injection . 8 . Chronic AF AF time cell injection . 9 . Unprotected leave main coronary artery disease &gt; 50 % . 10 . Ischemic hemorrhagic stroke diagnose CT/MRI event within last 3 month prior enrollment . 11 . Bleeding diathesis disorder abnormal coagulation profile preclude perform mapping/injection procedure . 12 . Serum glucose level &gt; 400 mg/dl within 28 day study procedure . 13 . Serum glucose level 300 400 mg/dl presence urine ketone within 28 day study procedure . 14 . Creatinine level ≥ 2.5 mg/dL within 28 day study procedure . 15 . Hematocrit ≤ 32 % within 28 day study procedure . 16 . White Blood Cell count &gt; 12 x 106/mm3 within 28 day study procedure . 17 . Platelet count ≤100 x106/mm3 within 28 day study procedure . 18 . Total bilirubin &gt; 3 mg/dL , albumin &lt; 2.8 g/dL , aspartate aminotransferase ( AST ) ≥ 2.5x upper limit normal , gamma glutamyltranspeptidase ( GGT ) ≥ 1.5x upper limit normal within 28 day study procedure . 19 . Presence ≥ 20 % antiHLA antibody titer and/or antibody specificity donor HLA antigen . 20 . A known hypersensitivity dimethyl sulfoxide ( DMSO ) , murine and/or bovine product . 21 . History cancer prior screen ( exclude basal cell carcinoma ) . 22 . Acute chronic infectious disease , include limited human immunodeficiency virus ( HIV ) . 23 . Any concurrent disease condition , opinion investigator , would make subject unsuitable participation study . 24 . Treatment and/or uncompleted followup treatment investigational . therapy within 6 month procedure intent participate investigational drug cell therapy study 3year followup period study . 25 . Active participation research therapy cardiovascular repair/regeneration . 26 . Prior recipient stem precursor cell therapy cardiac repair .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
</DOC>